sulfasalazine has been researched along with Stomach Neoplasms in 5 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Stomach Neoplasms: Tumors or cancer of the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "xCT protein is up-regulated in gastric cancer specimens and cells." | 1.62 | Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use. ( Guan, G; Liu, X; Yang, Y; Zhang, Y; Zhuang, J, 2021) |
| "The human gastric cancer cell line MKN28 was transfected with pRc/CMV plasmids encoding human CD44 or CD44v9, which were used for in vitro and in vivo experiments." | 1.48 | Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression. ( Hirata, K; Kanai, T; Matsuzaki, J; Miyoshi, S; Mori, H; Saya, H; Suzuki, H; Tsugawa, H, 2018) |
| "Sulfasalazine (SSZ) is an inhibitor of xCT and was shown to suppress the survival of CD44v-positive stem-like cancer cells both in vitro and in vivo." | 1.46 | Dose-escalation study for the targeting of CD44v ( Doi, T; Einaga, Y; Fukutani, M; Hasegawa, H; Hironaka, S; Imamura, CK; Ishii, Y; Kuwata, T; Nagano, O; Nakajima, TE; Nomura, S; Ohtsu, A; Ozeki, T; Sato, A; Saya, H; Shitara, K; Takahashi, S; Tsuchihashi, K, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhuang, J | 1 |
| Liu, X | 1 |
| Yang, Y | 1 |
| Zhang, Y | 1 |
| Guan, G | 1 |
| Shitara, K | 2 |
| Doi, T | 2 |
| Nagano, O | 3 |
| Fukutani, M | 2 |
| Hasegawa, H | 2 |
| Nomura, S | 2 |
| Sato, A | 2 |
| Kuwata, T | 2 |
| Asai, K | 1 |
| Einaga, Y | 2 |
| Tsuchihashi, K | 3 |
| Suina, K | 1 |
| Maeda, Y | 1 |
| Saya, H | 4 |
| Ohtsu, A | 2 |
| Miyoshi, S | 1 |
| Tsugawa, H | 1 |
| Matsuzaki, J | 1 |
| Hirata, K | 1 |
| Mori, H | 1 |
| Kanai, T | 1 |
| Suzuki, H | 1 |
| Wada, T | 1 |
| Ishimoto, T | 1 |
| Seishima, R | 1 |
| Yoshikawa, M | 1 |
| Oshima, H | 1 |
| Oshima, M | 1 |
| Masuko, T | 1 |
| Wright, NA | 1 |
| Furuhashi, S | 1 |
| Hirashima, K | 1 |
| Baba, H | 1 |
| Kitagawa, Y | 1 |
| Imamura, CK | 1 |
| Ozeki, T | 1 |
| Ishii, Y | 1 |
| Takahashi, S | 1 |
| Nakajima, TE | 1 |
| Hironaka, S | 1 |
1 trial available for sulfasalazine and Stomach Neoplasms
| Article | Year |
|---|---|
Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Surviv | 2017 |
4 other studies available for sulfasalazine and Stomach Neoplasms
| Article | Year |
|---|---|
Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use.
Topics: Amino Acid Transport System y+; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Biomarkers, Tumo | 2021 |
Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Resist | 2018 |
Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia.
Topics: Adenocarcinoma; Amino Acid Transport System y+; Animals; Biomarkers, Tumor; Cell Transformation, Neo | 2013 |
Dose-escalation study for the targeting of CD44v
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cell Proliferation; Dose-Re | 2017 |